Business Wire

iBASIS Partners With Mavenir to Launch CPaaS and Introduce Global Programmable Communications to Service Providers

Share

Today iBASIS, the leading provider of communications solutions for operators and digital players worldwide, announces the launch of its Carrier Communications Platform-as-a-Service (CPaaS) offering in partnership with Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects.

Since the COVID-19 pandemic began, businesses have accelerated their digital transformation programs as they’ve sought to enhance and personalize customer engagement applications with real-time and programmable communications.

Mavenir is a global CPaaS enablement partner with the power to service communications service providers (CSPs) of all sizes and provides the cloud-native platform, offering a complete set of programmable cloud communications capabilities, turnkey applications, and go-to-market assistance and training, to ensure that service providers go to market quickly.

iBASIS brings global coverage for voice, data, and messaging services, technology leadership, and a track record of quality, support and value. This creates a unique CPaaS offering that enables the addition of next-generation features into existing and new processes and software applications, in a frictionless manner, using application programming interfaces (APIs).

The iBASIS offering ranges from voice, messaging, e-commerce, and direct access to call centers across finance, healthcare, government applications, and other verticals. Businesses can now add real-time chat functionality with one-click calling via an app, and push out SMS messages to engage with their customers.

Ian Maclean, SVP, GM, Cloud Services at Mavenir, says “The integration of Mavenir's extensive CPaaS knowledge, tested platform, and best-of-breed applications with iBASIS global carrier network, voice, and messaging expertise and carrier channel reach, will unlock a market rife with opportunities for communication service providers, mobile operators and enterprise customers.”

As an independent communications specialist, iBASIS enables carriers and service providers to service their enterprise customers using their existing, trusted partners through its innovative “Bring Your Own Carrier” (BYOC) model, which is out-of-the-box, ready-to-go, and can be white-labeled.

“For too long, global telecom companies have been losing market share to new communication service providers. Through the Mavenir partnership, iBASIS is now accelerating CPaaS to telcos worldwide, enabling the digital transformation of their customer base quickly,” said Guillaume Klein, VP, Product Management at iBASIS. “The Mavenir CPaaS platform allows us to add digital transformation capabilities such as programmable SMS and voice, as well as critical market applications, such as the campaign management tool for SMS and voice calls, two-factor authentication, number masking, contact center services, and a broad portfolio of programmable communications.”

Additional Information

At Enterprise Connect (21 March – 24 March 2022), iBASIS and Mavenir will be hosting joint CPaaS solution demos. Click here to book a meeting.

* IDC: Market Analysis Perspective: Worldwide Communications Platform as a Service, 2021

About iBASIS

iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 21 offices worldwide. For more information, please visit iBASIS.com.

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

iBASIS
Melissa Coffman
26FIVE Global Lab
202.251.1793
iBASIS@26FIVE.com

Mavenir
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye